Warfarin treatment and risk of stroke among primary care patients with atrial fibrillation

References

• Forslund T, Wettermark B, Wandell P, et al. Risk scoring and thromboprophylactic treatment of patients with atrial fibrillation with and without access to primary healthcare data: experience from the Stockholm health care system. Int J Cardiol. 2013;170:208–214.
   PubMed Web of Science ®Google Scholar
• Hobbs FR, Taylor CJ, Jan Geersing G, et al. European primary care cardiovascular society (EPCCS) consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care. Eur J Prev Cardiol. 2016;23:460–473.
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991;22:983–988.
   PubMed Web of Science ®Google Scholar
• Michelena HI, Powell BD, Brady PA, et al. Gender in atrial fibrillation: ten years later. Gend Med. 2010;7:206–217.
   PubMed Web of Science ®Google Scholar
• Forslund T, Wettermark B, Wandell P, et al. Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: experience from the Stockholm region. Eur J Clin Pharmacol. 2014;70:1477–1485.
   PubMed Web of Science ®Google Scholar
• Zhang JT, Chen KP, Zhang S. Efficacy and safety of oral anticoagulants versus aspirin for patients with atrial fibrillation: a meta-analysis. Medicine. 2015;94:e409.
   Google Scholar
• Kitago T, Marshall RS. Strategies for early stroke recovery: what lies ahead? Curr Treat Options Cardiovasc Med. 2015;17:356.
   PubMedGoogle Scholar
• Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA. 2001;285:2864–2870.
   PubMed Web of Science ®Google Scholar
• Lip GY, Frison L, Halperin JL, et al. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke. 2010;41:2731–2738.
   PubMed Web of Science ®Google Scholar
• Patti G, Cavallari I. Patients with atrial fibrillation and CHA2DS2-VASc score 1: “to anticoagulate or not to anticoagulate? That is the question!”. Heart Rhythm. 2015;12:2515–2520.
   PubMed Web of Science ®Google Scholar
• Carlsson AC, Wandell P, Sundquist K, et al. Differences and time trends in drug treatment of atrial fibrillation in men and women and doctors' adherence to warfarin therapy recommendations: a Swedish study of prescribed drugs in primary care in 2002 and 2007. Eur J Clin Pharmacol. 2013;69:245–253.
   PubMed Web of Science ®Google Scholar
• Glazer NL, Dublin S, Smith NL, et al. Newly detected atrial fibrillation and compliance with antithrombotic guidelines. Arch Intern Med. 2007;167:246–252.
   PubMedGoogle Scholar
• Choudhry NK, Soumerai SB, Normand SL, et al. Warfarin prescribing in atrial fibrillation: the impact of physician, patient, and hospital characteristics. Am J Med. 2006;119:607–615.
   PubMed Web of Science ®Google Scholar
• Sundquist K, Li X. Coronary heart disease risks in first- and second-generation immigrants in Sweden: a follow-up study. J Intern Med. 2006;259:418–427.
   PubMed Web of Science ®Google Scholar
• Almgren T, Wilhelmsen L, Samuelsson O, et al. Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up. J Hypertens. 2007;25:1311–1317.
   PubMed Web of Science ®Google Scholar
• Aberg ND, Kuhn HG, Nyberg J, et al. Influence of cardiovascular fitness and muscle strength in early adulthood on long-term risk of stroke in Swedish men. Stroke. 2015;46:1769–1776.
   PubMed Web of Science ®Google Scholar
• Carlsson AC, Wandell P, Gasevic D, et al. Neighborhood deprivation and warfarin, aspirin and statin prescription - a cohort study of men and women treated for atrial fibrillation in Swedish primary care. Int J Cardiol. 2015;187:547–552.
   PubMed Web of Science ®Google Scholar
• Fang MC, Go AS, Chang Y, et al. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2008;51:810–815.
   PubMed Web of Science ®Google Scholar
• Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009;151:297–305.
   PubMed Web of Science ®Google Scholar
• Wandell P, Carlsson AC, Sundquist K, et al. Effect of cardiovascular drug classes on all-cause mortality among atrial fibrillation patients treated in primary care in Sweden: a cohort study. Eur J Clin Pharmacol. 2013;69:279–287.
   PubMed Web of Science ®Google Scholar
• de Koning JS, Klazinga NS, Koudstaal PJ, et al. The role of 'confounding by indication' in assessing the effect of quality of care on disease outcomes in general practice: results of a case-control study. BMC Health Serv Res. 2005;5:10.
   PubMed Web of Science ®Google Scholar
• Sjalander S, Sjalander A, Svensson PJ, et al. Atrial fibrillation patients do not benefit from acetylsalicylic acid. Europace. 2014;16:631–638.
   PubMed Web of Science ®Google Scholar
• Koster M, Asplund K, Johansson A, et al. Refinement of Swedish administrative registers to monitor stroke events on the national level. Neuroepidemiology. 2013;40:240–246.
   PubMed Web of Science ®Google Scholar
• Roldan V, Marin F, Manzano-Fernandez S, et al. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2013;62:2199–2204.
   PubMed Web of Science ®Google Scholar
• Carlsson AC, Wandell P, Osby U, et al. High prevalence of diagnosis of diabetes, depression, anxiety, hypertension, asthma and COPD in the total population of Stockholm, Sweden - a challenge for public health. BMC Public Health. 2013;13:670.
   PubMed Web of Science ®Google Scholar